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Background.—Migraine impacts more than 36 million 
people in the United States and 1 billion people worldwide. 
Despite the increasing availability of acute and preventive 
therapies, there is still tremendous unmet need. Potential 
treatments in development include monoclonal antibodies 
(mAbs). Appropriate use of these “biologic” treatments will 
necessitate an understanding of the aspects that distinguish 
them from traditional medications.
Aim.—Many drug classes are prescribed for migraine treatment, 
but all have limitations. Recently, calcitonin gene-related peptide 
(CGRP) activity has shown a significant promise as a target for 
preventive therapy. In this review, we provide an overview of the 
potential role of CGRP mAbs in migraine, with a focus on their 
design, pharmacokinetics, safety, and immunogenicity.
Conclusions.—The CGRP mAbs are an innovative new 
therapy for migraine and address the need for effective and 
tolerable preventive options. MAbs, including those that target 
CGRP or its receptor, bind to a target with high specificity and 
affinity and lead to few off-target adverse effects, although 
mechanism-based adverse reactions may occur. Unlike other 
therapeutic antibodies used to treat neurologic disease, CGRP 
mAbs do not have a target within the immune system and have 
been designed to avoid altering the immune system. The safety 
and efficacy of mAbs against CGRP or its receptors are being 
investigated in clinical development programs, and the first of these 
therapies has received regulatory approval in the United States.
Key words: migraine, CGRP, therapeutic antibodies, anti-CGRP 
mAbs for migraine
INTRODUCTION
Migraine is a common disabling primary headache disorder 
that affects more than 36 million people in the United States1 
and 1 billion people worldwide.2 Migraine has a substantial im-
pact on patients’ physical, social, and occupational functioning, 
as well as health care expenses and lost productivity of up to $36 
billion annually in the United States.2 Despite the increasing 
availability of acute and preventive therapies, there remains a 
high unmet need.2,3 For example, while 38.8% of people with 
migraine would benefit from preventive treatment, only 5-13% 
receive it.4,5 Potential treatments under development include 
monoclonal antibodies (mAbs).3 Appropriate use of these bio-
logic treatments will necessitate an understanding of the aspects 
that distinguish them from traditional medications.
DISCUSSION/OBSERVATIONS
Treatment Targets for Migraine
The pathophysiology of migraine is being actively explored 
and better understood. Evidence supports that migraine is a 
neurobiological disorder that arises from disturbances of cor-
tical and/or brainstem activity, including cortical spreading 
depression (CSD), activation of the trigeminovascular system, 
neurogenic inflammation, and central sensitization.6,7
Many drug classes are prescribed for migraine treatment, 
but the only currently available medication class specifically 
developed to treat migraine is the triptan class. Triptans pri-
marily target 5-HT1B/1D receptors as agonists for acute treat-
ment. It is believed that triptans abort a migraine attack by 
modulating trigeminal nociceptive pathways, in part by 
inhibiting calcitonin gene-related peptide (CGRP) release 
through activation of serotonin receptors.5,7 Other acute and 
preventive treatments were appropriated from other medical 
indications, and their mechanisms of action are less well un-
derstood.8 Many are associated with low tolerability and poor 
1-year adherence rates.5,9
[The copyright line for this article was changed on November 26, 2018, after original 
online publication.]
1690 | Headache | November/December 2018
Improved understanding of migraine pathophysiology has 
led to therapies with novel targets (eg, selective 5-HT1F recep-
tors, the SP-NK1R system, CGRP, nitric oxide synthase, gluta-
mate receptors).3,10 The CGRP molecule is currently the focus 
of therapies in development for migraine prevention. It is the 
most abundant neuropeptide in the trigeminal nerve and seems 
intimately linked to migraine pathogenesis.11 MAbs targeting 
CGRP or its receptor are the only therapies specifically designed 
for prevention of migraine.3,8 In preparation for these develop-
ments, we provide an overview of the role of CGRP in migraine 
and a discussion of mAbs, including their design, pharmacoki-
netics, safety, and interpretation of immunogenicity data.
CGRP
CGRP is a 37-amino acid peptide with 2 isoforms, α and β, 
that differ by only 3 amino acids. CGRPα is present primar-
ily in central and peripheral nervous system, and β is primarily 
found in enteric sensory neurons. Both isoforms are complete 
agonists of the CGRP receptor. Specific to the CNS, CGRP is 
apparently involved in pain modulation, perception, and cen-
tral sensitization, making it a potential target for migraine and 
other primary headache disorders. CGRP also has expression in 
non-neuronal tissues. It is a potent vasodilator and has a variety 
of additional biological effects, including on cardiac, smooth, 
and skeletal muscle; skin; the endocrine system; and the gastro-
intestinal system.11–13
CGRP binds strongly to both the canonical CGRP recep-
tor (composed of the calcitonin receptor-like receptor [CLR] 
and receptor activity-modifying protein 1 [RAMP1]); and the 
amylin 1 (AMY1) receptor (formed by a complex of the cal-
citonin receptor [CTR] with RAMP1). Binding of the ligand 
CGRP to CGRP receptors activates multiple intracellular path-
ways, including adenylyl cyclase and the cyclic adenosine mono-
phosphate (cAMP)‒signaling pathway. Association of receptor 
component protein (RCP) with the CGRP receptor is important 
for optimal signal transduction. CGRP binds with lower affinity 
to adrenomedullin receptors (formed by CLR and RAMP2 [ad-
renomedullin 1 {AM1} receptor] or CLR and RAMP3 [AM2] 
receptor) and other amylin receptors (formed by calcitonin re-
ceptor and RAMP2 [AMY2] or RAMP3 [AMY3]).11,13,14
There is compelling evidence of the involvement of CGRP 
in migraine pathophysiology.3,8 CGRP is elevated in external 
jugular venous blood during a migraine attack and in peripheral 
blood of patients who experience migraines even when they are 
not experiencing a migraine attack.15 Additionally, intravenous 
CGRP infusion into people with migraine can trigger migraine 
symptoms.16,17
In migraine pathophysiology, activated trigeminal nerves 
release CGRP, other vasoactive peptides such as vasoactive 
intestinal peptide, and classic neurotransmitters, like serotonin, 
that cause the subsequent release of proinflammatory media-
tors.13 These mediators further increase CGRP synthesis and 
release over hours to days, corresponding to the 4- to 72-hour 
duration of a typical migraine episode.15 Additionally, amelio-
ration of migraine pain after treatment with sumatriptan cor-
relates to the return of CGRP levels to normal after elevation 
during the migraine attack.18 See Figure 1 for a schematic of the 
proposed role of CGRP in migraine pathophysiology.
A role for targeting CGRP in migraine has been established 
through clinical trials of various CGRP-targeting therapies. 
Initially, CGRP was targeted for the acute treatment of mi-
graine with small-molecule CGRP antagonists (gepants). These 
therapies offered efficacy similar to published results for some 
oral triptans, but initial development programs were halted due 
to observed hepatotoxicity associated with some of these drugs. 
However, new gepants are in development.19
Most recently, mAbs with CGRP-modulating effects show 
a significant benefit in patients with episodic and chronic 
migraine.20-24
Antibodies and Therapeutic Antibodies
Endogenous antibodies are produced when B cells are acti-
vated after they encounter an antigen, and then mature into 
plasma cells that produce a specific antibody to that particu-
lar antigen.8,25,26 Immunoglobulin G (IgG) makes up 70% 
of all immunoglobulins and accounts for the majority of an-
tibody-based immunity against invading pathogens.25 Human 
IgG consists of 4 subclasses (isotypes), which are numbered in 
order of decreasing serum concentrations (IgG1, IgG2, IgG3, 
and IgG4).25,26 The 4 subclasses share 90% identity of over-
all amino acid sequence and are identical in the constant re-
gions.26,27 Antibody structure is shown in Figure 2.
While endogenous antibodies function to present foreign 
substances to the immune system in order to clear them and 
activate the immune system, it is possible to engineer mAbs – 
made from one clone of plasma cells – with high specificity. 
Because of this, mAbs are promising therapeutic candidates for 
many diseases.28 Approved mAb therapies currently exist for 
a number of diseases, such as rheumatoid arthritis or multiple 
sclerosis.28,29 Highly effective therapeutic mAbs have been used 
since 1985 (muromonab-CD3 for transplant rejection).30 At 
the time of writing, of 81 US Food and Drug Administration 
(FDA)-approved therapeutic mAbs, only 6 are available for 
indications other than oncology, autoimmune, or infectious 
disease, and only 3 are non-immunomodulatory therapies for 
chronic disease (PCSK9 inhibitors evolocumab and alirocumab 
to treat hypercholesterolemia, and Factor IX/X inhibitor emici-
zumab for the treatment of hemophilia A).29
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Since they are foreign substances, therapeutic mAbs may in-
duce an immune response. Initial therapeutic antibodies were 
produced from murine hybridomas (the fusion of murine my-
eloma cells and B cells to generate fusion cell lines with unique 
specificity); however, due to their high murine sequence content, 
they had high immunogenicity and short half-lives, which lim-
ited their application and led to the search for alternatives.28,31 
Currently, multiple methods, such as transgenic mice, comple-
mentarity-determining region grafting, and phage display tech-
niques, are used for the commercial production of humanized or 
human mAbs (sequences either closely resemble or are identical 
to human Ig sequences), which reduces immunogenicity.32,33
Importantly, although mAbs are engineered to reduce im-
munogenicity,34 some mAbs are specifically designed to 
target molecules within the immune system (eg, mAbs for 
autoimmune diseases) and thereby induce an immunologic ef-
fect.28 Others, such as recently developed anti-CGRP mAbs, 
have been engineered to bind to either the CGRP peptide or 
receptor with high specificity and thus have minimal interac-
tion with the immune system.8 In contrast to mAbs that are 
designed to bind immune cells or molecules in the immune 
system (eg, mAbs indicated for multiple sclerosis), mAbs that 
are engineered to target molecules outside the immune system 
(eg, mAbs targeting CGRP and its receptor) have no immuno-
modulatory effect.
Therapeutic mAbs differ from small-molecule drugs in sev-
eral ways that provide them with unique advantages and disad-
vantages (Table 1).8 MAbs primarily have extracellular targets, 
while small molecules can have both extracellular and intracel-
lular targets.8,35 The high target specificity (and thus reduced 
chance for off-target effects) and long half-life of mAbs give 
them a benefit over small molecules, especially in the treatment 
of chronic diseases like migraine.28,35 However, they need to be 
administered parenterally and, as noted, are potentially immu-
nogenic.35 Advances in mAb engineering may help to further 
enhance target specificity and reduce immunogenicity.36
Fig. 1.—Calcitonin gene-related peptide (CGRP) in migraine. CGRP may contribute to migraine by affecting: (A) Neurogenic inflammation; 
(B) blood flow in cerebral vessels; and (C) pain transmission. [Color figure can be viewed at wileyonlinelibrary.com] [Correction added after 
first online publication on November 26, 2018: Figure swapped with Figure 2.]
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IgG is the most common Ig class and is used as the back-
bone for therapeutic antibodies.29 Endogenous IgG isotypes 
have differing characteristics, but these differences may not 
be relevant to engineered antibodies. Regardless of the choice 
of subclass backbone, generation of highly specific and potent 
mAbs involves engineering the fragment crystallizable (Fc) re-
gion of the IgG to minimize effector cell activity and max-
imize manufacturability, as well as engineering the variable 
regions to further improve therapeutic properties, and limit 
immunogenicity.36
Antibody Pharmacokinetics
Currently, mAbs are delivered through parenteral routes of 
administration, primarily intravenous (IV) and subcutaneous 
(SC), because of their large size and hydrophilicity, which limit 
absorption from the gastrointestinal epithelium. In addition, 
they have a high propensity to denature in the stomach and 
degrade in the gastrointestinal tract.31,37
Peak concentrations achieved with parenteral extravascular 
routes of administration are lower than those achieved with IV 
routes.31 Absorption into systemic circulation for extravascular 
routes occurs through the lymphatic system, and the slow flow 
rate of lymph flow results in relatively slower absorption follow-
ing SC injections, taking approximately 2-8 days to reach peak 
plasma concentrations.31 However, since half-lives of mAbs may 
be considerably longer than the time to peak concentration,31 
differences between SC and IV routes are likely only clinically 
relevant for applications where rapid systemic circulation or 
high concentrations are required.
Antibodies are largely confined to the vasculature; they likely 
reach their target tissues through extravasation via convective 
transport.31 IgG concentration in the brain relative to plasma 
is low (~1:500) due to the size of the molecule, inefficient con-
vection uptake to the brain, rapid turnover of brain interstitial 
fluids, and, perhaps, the active efflux of antibodies from the 
brain tissue by Fc receptors (FcRns).31
MAbs are large molecules, so they are not filtered by the 
kidney for excretion into the urine as intact molecules. MAbs 
are catabolized by phagocytes (eg, macrophages, monocytes) of 
the reticuloendothelial system (RES) into peptides and amino 
acids. They may also be eliminated by target-mediated routes 
through internalization within the target-expressing cells and 
through intracellular breakdown within the lysosome or non-
specific endocytosis/pinocytosis.8,31
Fig. 2.—Structure of Ig. Antibodies are composed of 2 identical heavy and light chains that join to form the characteristic “Y” shape. The light 
chain contains 1 variable domain and 1 constant domain. The heavy chain contains 1 variable domain and 3 constant domains. Each antibody 
has an Fc region – the stem of the “Y,” which determines the effector function – and a Fab domain, the arms of the “Y.” The variable domains 
of each chain include a framework region and 3 CDRs, also referred to as hypervariable regions. The set of CDRs constitutes the paratope, the 
antigen-binding site that recognizes the epitope of a specific antigen. IgG (~150,000 Da) is shown next to aspirin (~180 Da) for a comparison 
between antibodies and small molecules. CH = heavy chain constant; CL = light chain constant; FV = variable fragment; VH = heavy chain 
variable; VL = light chain variable. [Color figure can be viewed at wileyonlinelibrary.com] [Correction added after first online publication on 
November 26, 2018: Figure swapped with Figure 1.]
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The main factor that influences the half-life of therapeutic 
mAbs is the interaction of the IgG with the neonatal FcRn on 
the cell surface. The long half-life of endogenous antibodies is 
the consequence of antibody salvage from lysosomal degrada-
tion by FcRn. MAbs can be engineered with increased half-
lives by alteration of the IgG Fc amino acids.28,31,38 The average 
serum half-life of therapeutic IgG varies widely but is much 
longer than that of small-molecule drugs, allowing them to be 
administered with typical frequencies ranging from every other 
week to yearly.29
Factors that affect antibody pharmacokinetics include the 
properties of the antibody (eg, origin, structure, size, concentra-
tion, and affinity), properties of the antigen or target (eg, dis-
tribution, concentration), and patient characteristics (eg, body 
mass index, sex, age, activity level).28
MAbs targeting CGRP and its receptor have pharmacoki-
netic properties typical of other therapeutic antibodies. Hence, 
they are administered parenterally with frequencies ranging 
from monthly to quarterly.39
Antibody Safety
Safety risks associated with mAbs can be divided into 2 major 
categories: on-target and off-target. On-target modulation may 
cause adverse effects or potential safety concerns because of 
downstream effects related to intended activity. For example, 
in therapies approved for treatment of multiple sclerosis, some 
mAbs target the immune system directly by binding to sites on 
T cells or B cells. While these treatments have shown high ef-
ficacy related to modulation of the immune system, the same 
modulation may increase the risk of unwanted effects (eg, oppor-
tunistic infections or malignancies) resulting from the change 
in immune response.34,40 Target-based toxicities may also arise 
for therapies with targets other than immunomodulation. For 
example, mAbs used for various cancers may cause dermatolog-
ical toxicity, cardiotoxicity, and bleeding complications result-
ing from the modulation of EGFR, HER2, and angiogenesis, 
respectively.8 Since CGRP is involved in many organ systems, 
there is the potential for target-related adverse events. These 
could conceivably include unwanted effects on systems related 
to cardiovascular, gastrointestinal, endocrinological, and wound 
healing function. However, clinical trials of mAbs intended to 
modulate CGRP showed no clinically meaningful differences 
between the active treatment arms and the placebo arms for 
the results of hepatic-function testing, creatinine levels, total 
neutrophil counts, vital signs, or electrocardiographic findings 
during the treatment periods.20-24 Moreover, patient-reported 
adverse effects have generally differed minimally between active 
and placebo groups in clinical studies. Patients with diseases af-
fecting relevant organs are typically excluded from clinical tri-
als; therefore, the effects of CGRP modulation in these patients 
are unknown.
Because of their high specificity, there is low risk of mAbs 
nonspecifically binding to unintended cells or tissues, causing 
off-target-related adverse events.8 For example, to achieve their 
intended result of lowering low-density lipoprotein (LDL) lev-
els, PCSK9 inhibitors bind to and neutralize PCSK9, which 
in turn prevents reabsorption of the LDL receptor, resulting 
in a dramatic lowering of LDL. These therapies demonstrate 
excellent safety profiles (with essentially no off-target adverse 
effects), in addition to improved cardiovascular outcomes.41 
CGRP-modulating mAbs have so far reported similarly low 
risks of off-target-related toxicities.3,39
Table 1.—Summary of Comparison of Small-Molecule Drugs and Antibody Therapies
Monoclonal Antibodies Small-Molecule Drugs
Target specificity High Lower
Size High MW (~150,000 g/mol) Low MW (<0.9 g/mol)
Molecule Protein Chemical
Targets Extracellular Intracellular/extracellular
Primary administration Parenteral All routes
Half-life (t1/2) Long; often days to weeks Short; often hours
Dosing frequency Every other week to yearly Often dosed ≥1 time per day
Drug-drug interactions Rare Many examples
Metabolism pathway Catabolism; degraded to peptides or amino acids Mainly by CYP and phase II enzymes; metabolized to nonactive and active metabolites
Excretion Mostly recycled as peptide fragments by the body Liver, kidney
Potential for immunogenicity Yes No
API/production process Culture derived Synthesized
API = active pharmaceutical ingredient; CYP = cytochrome P450; MW = molecular weight.
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Due to technical advances, it is now possible to produce 
mAbs with very little antigenic material (ie, little to no mu-
rine components).32,33 As a result, serious off-target immuno-
genic adverse effects, such as anaphylaxis and serum sickness 
that affected early murine mAbs, have been dramatically 
minimized, as discussed below (Immunogenicity section). 
Off-target effects for modern mAbs relate more to tolerability 
and are most commonly associated with route of administra-
tion, resulting, for example, in injection site reactions with SC 
administration, which may include swelling, itching, redness, 
and pain. An IV route is less likely to cause injection site reac-
tions since it is delivered directly into the vascular system.8,34
Clinical trial results of CGRP-modulating mAbs indicate 
that treatment-emergent adverse events that investigators con-
sidered possibly related to treatment were not significantly dif-
ferent among the active treatment and placebo groups. Adverse 
events that occurred were largely reactions at the injection site 
in those mAbs subcutaneously administered.20-24
Since IgG is known to be transported into the placenta by 
the FcRn, and a significant portion of migraine patients are 
women of reproductive age, safety considerations in pregnancy 
will need further study.2,26 Additionally, since clinical trials for 
these mAbs were up to 12 months in duration, the long-term 
safety of CGRP modulation has not been established.20-24
Immunogenicity
As with all therapeutic biologics, mAbs may be recognized 
as foreign, resulting in an immune response and the creation 
of antidrug antibodies (ADAs).8 This immunogenicity is influ-
enced by both drug- and patient-related factors.42 The clini-
cal consequences of ADAs may range from no apparent effect 
to loss of efficacy, alteration of half-life, or, rarely, significant 
adverse effects.8,43 ADAs are termed non-neutralizing if they 
are directed against the non-antigen-binding region and do not 
affect binding of the therapeutic antibody to its target. They 
are neutralizing if they are directed against the portion of the 
variable region of the antibody that confers antigen specificity 
or interfere with target binding.43
Immunogenicity was long felt to be only associated with 
the fraction of foreign sequence in the therapeutic antibody. 
However, it has recently become apparent that immunogenic-
ity of therapeutic mAbs also arises from immune responses di-
rected against the variable regions of the mAb.44 Human and 
humanized antibodies carry a lower risk for inducing immune 
responses in humans than mouse or chimeric antibodies, but 
even human sequence-derived antibodies can induce ADAs.42-44 
While International Nonproprietary Name conventions pre-
viously dictated that the portion of murine-derived mate-
rial be specified with a source infix (eg -xi-, -zu-), new mAb 
nomenclature guidance discontinues the use of the source infix, 
emphasizing the observation that human and humanized mAbs 
do not substantially vary in immunogenicity and that this 
should not be used as a differentiator between mAbs.45
Measurement of and subsequent clinical implications of 
ADAs vary among products. Detection of ADA formation 
is highly dependent on the sensitivity and specificity of the 
assay, and the observed incidence of ADAs may be inf luenced 
by factors such as method, sample handling, timing of sample 
collection, concomitant medications, and disease condition. 
Therefore, the FDA cautions against comparison of ADA 
incidence between different mAbs, even for products that 
share sequence or structural homology.44 Further, while en-
dogenous antibodies are generally present in concentrations 
of approximately 10 mg/mL, and most therapeutic mAbs are 
administered at concentrations <10 µg/mL,31 FDA guidance 
mandates that assays for ADAs should have detection limits 
of <100 ng/mL.44 Thus, detection of ADAs does not imply 
any clinical effect.8 Further complicating the interpretation 
of ADA results, literature suggests that even patients who are 
naive to a therapy can have preexisting ADAs to that ther-
apy.44 Moreover, while incidence of ADAs and neutralizing 
ADAs is generally reported, especially in product labeling, 
the clinical impact of ADAs may be associated with ADA 
titer and persistence rather than incidence.44 Therefore, when 
considering ADAs in the clinical context, it is the clinical 
effect which is of true importance. If there is no change in 
efficacy or safety, the presence of ADAs is of no clinical im-
portance.8 Reported data for ADAs for CGRP-modulating 
mAbs are limited, but no impact of ADA development on 
efficacy or safety has been demonstrated.46
Summary
Anti-CGRP mAbs are an innovative new therapeutic class 
for migraine. They address the significant need for more effi-
cacious and tolerable preventive options. They are the first pre-
ventive therapies designed specifically for migraine.
The promise of CGRP-targeting therapies was first demon-
strated by small-molecule therapies targeting the CGRP re-
ceptor. These were shown to be highly efficacious in acute 
treatment of migraine, with efficacy comparable to that in the 
best published reports of oral triptans. However, the early ge-
pants caused hepatotoxicity, and newer gepants will have to be 
assessed carefully.
At the time of writing, several mAbs targeting either the 
CGRP ligand or receptor are in development, and 3 have been 
approved by the FDA. In contrast with small molecules, mAbs 
have low potential for off-target effects, and have long half-
lives, making them good candidates for chronic diseases like 
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migraine. Importantly, unlike small molecule drugs, mAbs are 
degraded and eliminated like endogenous IgGs via the RES 
rather than through metabolic pathways. Therefore, mAbs 
targeting CGRP or its receptor are not expected to induce the 
hepatotoxicity seen with the initial gepants. However, CGRP 
mAbs need to be administered parenterally, and consideration 
should be given to the potential risks associated with that route.
While mAbs targeting CGRP or its receptor bind to their 
targets with high specificity and affinity, leading to few off-tar-
get adverse effects, it is important to keep in mind that mecha-
nism-based toxicities may occur. These might involve vascular, 
gastrointestinal, and other systems, but, to date, modulation of 
CGRP has been shown to cause only limited target-related toxic-
ities. Additionally, CGRP mAbs do not have a target within the 
immune system and have been designed to avoid alteration of 
the immune system, distinguishing them from other therapeutic 
antibodies currently approved to treat neurologic diseases.
As with all mAbs, immunogenicity may occur with mAbs 
targeting CGRP or its receptor, leading to formation of ADAs. 
Potential clinical effects of ADAs include loss of response, as 
well as hypersensitivity or allergic reactions. If there is no change 
in efficacy or safety, the presence of ADAs is of no clinical im-
portance. Since ADAs largely arise from immune response to 
the variable regions of mAbs, clinical differences in ADA ef-
fects between humanized and human mAbs are not expected. 
The translation of ADA data to clinical practice is challenging 
due to factors such as inability to adequately compare ADA in-
cidence between mAbs, and the reporting of ADA incidence 
rather than titer and persistence.
KEY CONCLUSIONS
1. The safety and efficacy of mAbs against CGRP or its 
receptors are currently being investigated in clinical de-
velopment programs, and the first group of these therapies 
has recently been approved.
2. Over time, we will understand the long-term safety of these 
mAbs, but the therapeutic benefit of this new class of mi-
graine treatment is promising for patients with inadequately 
controlled migraine.
3. It is important for clinicians to understand the aspects of 
these non-immunomodulatory mAb therapies that distin-
guish them from small-molecule therapies and other types of 
therapeutic mAbs.
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